Therapeutic ReviewAdvances in the Treatment of Metastatic Colorectal CancerKurkjian, Carla MD1; Kummar, Shivaani MD2* Author Information 1Department of Hematology/Oncology, University of Oklahoma, Oklahoma City, OK; and 2Medical Oncology Branch, Center for Clinical Research, National Cancer Institute, Bethesda, MD. Supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, Bethesda, MD. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. *Address for correspondence: Medical Oncology Branch, National Cancer Institute, 10 Center Drive, 10/12N226, Bethesda, MD 20892. E-mail: [email protected] American Journal of Therapeutics: September 2009 - Volume 16 - Issue 5 - p 412-420 doi: 10.1097/MJT.0b013e3181907ed9 Buy Metrics Abstract The treatment of metastatic colorectal cancer has undergone major advances yielding significant improvements in survival over the past decade. These advances have evolved due to the benefits of combination chemotherapy and the incorporation of biologic therapy. However, as we struggle to provide optimum care while sparing patients ineffective therapy and undue cost, the importance of tailored therapy to maximize benefit will become increasingly important. This article reviews the major advances in the treatment of patients with metastatic colorectal cancer and the burgeoning developments in individualized therapy. © 2009 Lippincott Williams & Wilkins, Inc.